ORBAS PLUS

Olmesartan Medoxomil and Hydrochlorothiazide

Cardiovascular

 
 
 
 
 


Indication

ORBAS PLUS 20/12.5 is indicated for the treatment of hypertension.


Dosage and Administration

Hypertension : The usual starting dose of ORBAS PLUS 20/12.5 is one tablet once daily. Depending on the blood pressure response, the dose may be titrated at intervals of 2-4 weeks to two tablets of ORBAS PLUS 20/12.5 once daily.

Patient with Renal impairment : The usual dose regimens of therapy with ORBAS PLUS 20/12.5 may be followed the patient’s creatinine clearance is > 30 mL/min. In patients with more severe renal impairment, loop diuretics are preferred to thiazides. So, ORBAS PLUS 20/12.5 is not recommended.

Patient with Hepatic impairment : No dosage adjustment is necessary with hepatic impairment. 

OR AS DIRECTED BY THE PHYSICIAN.


Composition

ORBAS PLUS 20/12.5: Each film-coated tablet contains Olmesartan Medoxomil INN 20 mg and Hydrochlorothiazide BP 12.5 mg.

 
 

Other Cardiovascular Products